DrugPatentWatch Database Preview» See Plans and Pricing
« Back to Dashboard
Summary for Patent: 5,876,942
|Title:||Process for sexing cow embryos|
|Abstract:||A rapid, highly reproducible and sensitive technique has been successfully developed for sexing the cow embryos, by method of polymerase chain reaction (PCR) against the amelogenin (bAML) genes located on both X- and Y-chromosomes of the Holstein dairy cattle. Results from DNA sequence analysis showed that there was only 45% homology between the intron 5 of AMLX and AMLY genes. Based on these sequences a pair of sex-specific primers, pbAML5XY(+) and pbAML5XY (-),were designed allowing to amplify a single fragment of 476-bp from the female cattle and two fragments of 476-bp and 341-bp from the male ones, respectively. The most important feature is that the precise sensitivity of sex-determination was confirmed to be reached as minimum template as trace amount of genomic DNA content in either a single lymphocyte or a single blastomere isolated from cow embryo at day-6 to day-7. Moreover, neither those of complicated procedures for purifying the DNA prior the PCR nor any extra pair of primers for serving as internal control is thought to be essential and the sex-determination of over hundred embryos can be completed at once within 4hrs.|
|Inventor(s):||Cheng; Winston Teng-Kuei (Taipei, TW), Chen; Chuan-Mu (Tai Chung, TW), Hu; Che-Lin (Taipei, TW), Wang; Chih-Hua (Taipei, TW), Choo; Kong-Bung (Taipei, TW)|
|Assignee:||National Science Council of Republic of China (Taipei, TW)|
|Patent Claims:||1. An oligonucleotide primer set for bovine embryo sexing wherein said oligonucleotide primer set comprises a primer pair which primer pair consists of individual
oligonucleotide primers each of which is able to hybridize specifically and simultaneously to an intron 5 sequence of the bovine amelogenin gene, which gene is located on both the bovine X and Y chromosomes, wherein said intron 5 sequence of the bovine
amelogenin gene is selected from the group consisting of: SEQ ID NO: 21 (the nucleotide sequence of intron 5 of the bovine amelogenin gene located on the bovine X chromosome), that sequence fully complementary to SEQ ID NO: 21, SEQ ID NO: 22 (the
nucleotide sequence of intron 5 of the bovine amelogenin gene located on the bovine Y chromosome), and that sequence fully complementary to SEQ ID NO: 22.
2. A primer pair, for sex determination of cow embryonic cells, which comprises a DNA sequence selected from the group consisting of:
5'-AAATTCTCTCACAGTCCAAG-3' (SEQ ID NO: 16); and
5'-CAACAGGTAATTTTCCTTTAG-3' (SEQ ID NO: 19).
3. A process for sexing a cow embryo comprising the following steps:
(a) isolating a single cow blastomere by micromanipulation and placing the blastomere sample into a low tonic solution, then heating under 97.degree. C. to denature its proteins and expose its genomic DNA;
(b) carrying out a PCR-sexing reaction by using a primer pair according to claim 2, wherein the concentration of the primer pair is increased from the conventional 100 nM to 400 nM, and the amount of thermostable Taq DNA polymerase in the reaction system is twice (2.5 U) that used in conventional PCR (i.e. 1.25U), and wherein said PCR-sexing reaction is carried out in a program having reaction conditions as follows: 94.degree. C., 30 seconds; 53.degree. C., 1 minute; 72.degree. C., 1 minute repeating 20 cycles; followed by 94.degree. C., 30 seconds; 54.degree. C., 1 minute; 72.degree. C., 1 minute repeating 30 cycles; and with a termination step as 72.degree. C., 5 minutes and 4.degree. C., 2 minutes, whereby PCR products are produced; and
(c) size separating said PCR products by electrophoresis, wherein PCR products derived from a female embryo(XX) has a length of 467-bp, while those products derived from a male embryo(XY) have lengths of 467-bp and 341-bp, thereby determining the sex type of the cow embryo.
4. A kit for sexing a cow embryo comprising a primer pair according to claim 1 and at least one reagent for performing PCR.
5. A process for sexing a cow embryo which comprises isolating a cow embryo and exposing its genomic DNA; carrying out PCR sexing reaction using the primer pair of claim 2 as primer to thereby obtain PCR products; and size separating said PCR products whereby the presence of 467 bp and 341 bp PCR products indicates a male embryo and the presence of only 467 bp PCR product indicates the presence of a female embryo.
6. A compound which is a oligonucleotide selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 21 and SEQ ID NO: 22.
7. A kit for sexing a cow embryo according to claim 4 wherein said at least one reagent is selected from the group consisting of: Taq DNA polymerase, dNTPs and 1X PCR buffer wherein said Taq DNA polymerase is present in an amount of 2.5 U; said dNTPs are present in an amount of 0.2 mM and said 1X PCR buffer contains: 20 mM Tris-HCl having a pH of 8.8, 10 mM (NH.sub.4).sub.2 SO.sub.4, 10 mM MgCl.sub.2,2 mM MgSO.sub.4, 0.1% Triton X-100 and 0.1 mg/ml BSA.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||001||1986-06-04||Start Trial||National Science Council of Republic of China (Taipei, TW)||2039-02-26||RX||search|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||002||1986-06-04||Start Trial||National Science Council of Republic of China (Taipei, TW)||2039-02-26||RX||search|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||003||1986-06-04||Start Trial||National Science Council of Republic of China (Taipei, TW)||2039-02-26||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.